Sitagliptin add-on to metformin plus sulphonylurea combination therapy: The efficacy of triple therapy on metabolic and glycemic control in type 2 diabetes

Abstract

Objectives: This study aimed to evaluate the efficacy of sitagliptin add-on metformin and sulphonylurea combination therapy in type 2 diabetic patients with insufficient glycemic control. Methods: This study included who were treated with sitagliptin and continued with sitagliptin for 12 months while receiving metformin-sulphonylurea combination. The fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) levels of the patients were measured at the initial, 3rd month, 6th month and 12th month. Results: A total of 40 patients were included in this study. The mean age patients was 59.2±9.6 years and initial HbA1c level was 7.6% (7.0-10.5). The HbA1c level of the patients was 6.8% (5.9-8.7) at 3 months, 6.7% (5.3-7.5) at 6 months, and 6.9% (5.4-9.1) at 12 months (p<0.001 for 0-3. months, p<0.001 for 0-6. months, p=0.003 for 0-12. months). Conclusion: Adding sitagliptin to the treatment is an effective and well-tolerated option in patients with type 2 diabetes who are not able to achieve adequate glycemic control despite metformin-sulphonylurea combination treatment. © 2021 by Anatolian Journal of Family Medicine.